Biosenta Announces Successful Launch of Bench Scale Production Plant and Exceeding Expectations of Tri-Filler(TM) Particle Encapsulation Technology
Biosenta Announces Successful Launch of Bench Scale Production Plant and Exceeding Expectations of Tri-Filler(TM) Particle Encapsulation Technology
Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - March 27, 2024) - Biosenta Inc. (CSE: ZRO) ("Biosenta" or the "Company") is pleased to announce a significant milestone in its technological and operational advancements with the successful construction and operation of a bench scale production plant. The results from this production not only surpassed our expectations, but also showcased that our patented Tri-Filler antimicrobial technology is ready for accelerated development and scaling towards industrial manufacturing applications.
安大略省多倫多和艾伯塔省卡爾加里--（Newsfile Corp.，2024年3月27日）——Biosenta Inc.（CSE：ZRO）（“Biosenta” 或 “公司”）很高興地宣佈，成功建造和運營了一座臺式生產工廠，這是其技術和運營進步的一個重要里程碑。此次生產的結果不僅超出了我們的預期，而且表明我們的專利Tri-Filler抗菌技術已準備就緒，可以加速開發並擴展到工業製造應用。
Operational Success and Optimizations
運營成功與優化
Biosenta has successfully constructed and commenced operations of a bench scale production plant, showcasing our capability to produce up to 15 kilograms of Tri-Filler daily. This marks a significant scale-up from our previous capacity, which was limited to smaller quantities for lab testing purposes only.
Biosenta 已成功建造並開始運營一座臺式生產工廠，展示了我們每天生產多達 15 千克的 Tri-Filler 的能力。這標誌着我們以前的產能大幅擴大，以前的產能僅限於較小的數量，僅用於實驗室測試目的。
CEO's Perspective
首席執行官的觀點
"This is an amazing achievement by Dr. Maen Husein and group. The optimized particles are now being tested in industrial manufacturing processes," says Am Gill, CEO of Biosenta Inc. This development is not just a step forward in antimicrobial technology but also a testament to our team's dedication and innovative spirit.
“這是Maen Husein博士及其團隊取得的一項了不起的成就。經過優化的顆粒現在正在工業製造過程中進行測試，” Biosenta Inc.首席執行官阿姆·吉爾說。這一發展不僅是抗菌技術向前邁出的一步，也是我們團隊的奉獻精神和創新精神的見證。
Promising Results and Future Directions
令人鼓舞的結果和未來方向
According to Dr. Maen Husein, "The initial runs of Tri-Filler have delivered beyond expectations, with particle quality surpassing pre-established benchmarks. These results validate both the antimicrobial efficacy of the particles and the design of the manufacturing unit." Next steps involve operation of the bench scale plant, aiming to produce sufficient Tri-Filler for pilot runs in various industrial processes such as coatings, concrete, drywall, plastics, and other vast materials in the construction industry. Plans for a commercial scale plant will follow.
根據梅恩·侯賽因博士的說法， “Tri-Filler 的初始運行效果超出了預期，顆粒質量超過了預先設定的基準。這些結果驗證了顆粒的抗微生物功效和製造單元的設計。” 接下來的步驟涉及檯秤工廠的運營，目標是生產足夠的三填充物，用於建築行業中塗料、混凝土、石膏板、塑料和其他大型材料等各種工業過程的試運行。隨後將計劃建造一座商業規模的工廠。
Research Collaboration with the University of Calgary
與卡爾加里大學的研究合作
In partnership with the University of Calgary, further investigations will assess the performance of the bench scale plant against diverse input grades. This collaboration is crucial for refining the industrial scale plant's optimization, paving the way for broader commercial applications of Tri-Filler technology.
與卡爾加里大學合作，進一步的調查將根據不同的投入等級評估該檯秤工廠的性能。這種合作對於完善工業規模工廠的優化至關重要，爲Tri-Filler技術的更廣泛商業應用鋪平了道路。
Looking Ahead
展望未來
The construction of an industrial scaleup plant is under active consideration, with further details and timelines to be shared. This move will significantly enhance our production capabilities and impact across multiple industries.
正在積極考慮建造工業規模化工廠，更多細節和時間表有待分享。此舉將顯著增強我們的生產能力和對多個行業的影響。
About Biosenta Inc.
關於 Biosenta Inc.
Biosenta Inc. is dedicated to the discovery, development, and commercialization of innovative antimicrobial products derived from its proprietary Tri-Filler technology. Based in Toronto, Ontario, Biosenta aims to revolutionize the way we combat microbes, offering solutions that are not only effective but also environmentally friendly and sustainable.
Biosenta Inc. 致力於發現、開發和商業化源自其專有Tri-Filler技術的創新抗菌產品。Biosenta總部位於安大略省多倫多，旨在徹底改變我們對抗微生物的方式，提供不僅有效而且環保和可持續的解決方案。
For further inquiries, please contact:
如需進一步查詢，請聯繫：
Am Gill, President and CEO, Biosenta Inc.
Email: info@biosenta.com
Phone: 416-410-2019
Am Gill，Biosenta Inc. 總裁兼首席執行官
電子郵件：info@biosenta.com
電話：416-410-2019
Biosenta is poised for a future where our antimicrobial technology plays a pivotal role in promoting public health and safety. Stay tuned for more updates as we continue to innovate and expand our reach.
Biosenta已爲我們的抗菌技術在促進公共健康和安全方面發揮關鍵作用的未來做好了準備。在我們繼續創新和擴大覆蓋範圍的同時，請繼續關注更多更新。
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements. Readers are cautioned that such statements are only predictions and involve risks and uncertainties that could cause actual events or results to differ materially.
本新聞稿包含前瞻性陳述。請讀者注意，此類陳述只是預測，涉及風險和不確定性，可能導致實際事件或結果出現重大差異。
For more information, visit our website:
欲了解更多信息，請訪問我們的網站：
譯文內容由第三人軟體翻譯。